Clarivate Epidemiology’s coverage of acute myeloid leukemia (AML) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
Acute myeloid leukemia (AML) is the most common form of leukemia in adults and has historically been associated with poor five-year overall survival rates. In recent years, the AML treatment…
Acute myeloid leukemia (AML) is the most common form of adult leukemia and has the lowest five-year overall survival rates of all blood cancers. Historically, the treatment of AML in China is…
Acute myeloid leukemia (AML) is the most common form of adult leukemia and has the lowest five-year overall survival rates of all blood cancers. Historically, the treatment of AML in China is…
Acute myeloid leukemia (AML) is the most common form of adult leukemia and has the lowest five-year overall survival rates of all blood cancers. Historically, the treatment of AML in China is…
Data Slicer
Data Slicer
Data Slicer
EPI Data Slicer
EPI Data Slicer
Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenias and the risk of progression to acute myeloid leukemia (AML). Although…
Acute myeloid leukemia (AML), the most common form of leukemia in adults, has historically been associated with poor five-year overall survival rates. AML is witnessing a paradigm shift from…
Acute myeloid leukemia (AML), the most common form of leukemia in adults, is associated with poor five-year overall survival rates. After years of chemotherapy-dominated treatment, the FDA approved…
Acute myeloid leukemia (AML), the most common form of leukemia in adults, is associated with poor five-year overall survival rates. After years of chemotherapy-dominated treatment, the FDA approved…